Clearmind Advances MDMA-PEA Patent For PTSD Treatment Amid FDA Psychedelic Drug Guidance

Clearmind Medicine (CMND) advanced its intellectual property portfolio with the U.S. publication of a patent application covering MDMA combined with N-acylethanolamines such as PEA for PTSD, anxiety and eating disorders.